Abstract
Objective To investigate HBV genotype in chronic hepatitis B (CHB) patients in Gansu province and analyze the relations between the drug resistance treated with analogues (NAs)such as adefovir dipivoxil (ADV) and HBV genotype,drug regimen.Methods Eighty-seven CHB patients were selected in the First Hospital of Lanzhou University from January 2009 to January 2011.According to the application of NAs therapy,patients were divided into treated group and control group.There were 75 patients in treated group,and 12 patients in untreated group(control group).HBsAg,liver function,HBV DNA,HBV genotypes and drug resistance points of both two group patients were detected.Results In all CHB patients,there were 72 cases (82.76%) with genotype C,9 cases (10.34%) with genotype B,5 cases (5.75%) with genotype D,1 case(1.15%) with genotype F.There were 48 cases with drug resistance in treated group,the rate of drug resistance was 64.00%; while 3 cases occurred drug resistance in control group,whose drug resistant rate was 25.00%.There were statistical differences between two groups (x2 =6.487,P < 0.05).18 cases used with ADV single-agent therapy in the treated group,the resistance rate of them was 61.11%.24 cases used with ADVsequential or combined treatment in the treated group,the resistance rate of them was 66.67%.There was no difference between the different medication way (x2 =0.138,P > 0.05).In the ADV treatment group,34 cases were genotype C,whose drug resistance rate was 70.59% ; 5 cases were genotype B,whose drug resistance rate was 60%.There were no differences between the different genotypes (P > 0.05).Conalusions The main HBV genotype in Gansu region is genotype C.ADV treatment of different genotypes of CHB patients may have small impaction on the drug resistance,as well as the medication way. Key words: Hepatitis B, chronic; Nucleoside analogues; Adefovir dipivoxil; Drug resistance; Genotype
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.